Targeting methionine with oral recombinant methioninase (o-rMETase) arrests a patient-derived orthotopic xenograft (PDOX) model of BRAF-V600E mutant melanoma: implications for chronic clinical cancer therapy and prevention. Issue 3 (1st February 2018)

• Record Type: Journal Article
• Authors: Kawaguchi, Kei; Han, Qinghong; Li, Shukuan; Tan, Yuying; Igarashi, Kentaro; Kiyuna, Tasuku; Miyake, Kentaro; Miyake, Masuyo; Chmielowski, Bartosz; Nelson, Scott D.; Russell, Tara A.; Dry, Sarah M.; Li, Yunfeng; Singh, Arun S.; Eckardt, Mark A.; Unno, Michiaki; Eilber, Fritz C.; Hoffman, Robert M.
• Is Part Of: Cell cycle. Volume 17:Issue 3(2018)
• Page Start: 356
• Page End: 361
• Publication Date: 2018-02-01
• Subjects: Recombinant methioninase -- methionine dependence -- oral administration -- pyridoxal-L-phosphate -- melanoma -- PDOX -- nude mice -- orthotopic; Cell cycle -- Periodicals; 571.84377
• DOI: 10.1080/15384101.2017.1405195
• Languages: English
• ISSNs: 1538-4101

Abstract

ABSTRACT: The elevated methionine (MET) use by cancer cells is termed MET dependence and may be the only known general metabolic defect in cancer. Targeting MET by recombinant methioninase (rMETase) can arrest the growth of cancer cells in vitro and in vivo. We previously reported that rMETase, administrated by intra-peritoneal injection (ip-rMETase), could inhibit tumor growth in a patient-derived orthotopic xenograft (PDOX) model of a BRAF-V600E mutant melanoma. In the present study, we compared ip-rMETase and oral rMETase (o-rMETase) for efficacy on the melanoma PDOX. Melanoma PDOX nude mice were randomized into four groups of 5 mice each: untreated control; ip-rMETase (100 units, i.p., 14 consecutive days); o-rMETase (100 units, p.o., 14 consecutive days); o-rMETase+ip-rMETase (100 units, p.o.+100 units, i.p., 14 consecutive days). All treatments inhibited tumor growth on day 14 after treatment initiation, compared to untreated control (ip-rMETase, p <0.0001; o-rMETase, p <0.0001; o-rMETase+ip-rMETase, p <0.0001). o-rMETase was significantly more effective than ip-rMETase ( p = 0.0086). o-rMETase+ip-rMETase was significantly more effective than either mono-therapy: ip-rMETase, p = 0.0005; or o-rMETase, p = 0.0367. The present study is the first demonstrating that o-rMETase is effective as an anticancer agent. The results of the present study indicate the potential of clinical development of o-rMETase as an agent for chronic cancer therapy and for cancer prevention and possibly for life extension since dietary MET reduction extends life span in many animal models.